DGAP-News: SphingoTec Accelerates Growth with Direct Sales vom 20.05.2021, 10:00 Uhr Bild: pixabay.com SphingoTec Accelerates Growth with Direct Sales 20.05.2021 / 10:00 The issuer is solely responsible for the content of this announcement. SphingoTec to expand the commercialization strategy by establishing a sales division and appointing new head of sales Tailored diagnostic solutions for point of care use Innovative proprietary biomarkers and standard parameters available on the fully automated Nexus IB10 platform Hennigsdorf/Berlin, Germany, May 20, 2021 - Diagnostics company SphingoTec GmbH ("SphingoTec") announces an expansion of its go-to-market strategy to scale its sales in Germany by creating a direct sales force for its integrated diagnostic solutions. SphingoTec will sell directly to healthcare providers its Nexus IB10 point of care platform together with a broad portfolio of assays. The rapid tests include commonly used parameters as well as innovative and proprietary biomarkers for critical care settings. The direct sales team will be complementing the already established distributor network and will drive commercialization going forward.